Provista Blog > A Different Approach to Breast Cancer Detection
The greatest promise for improving detection of breast cancer lies in the ability to identify early warning signals of breast cancer in the blood called “biomarkers.” With the scientific discovery of key protein biomarkers and protein signatures for breast cancer, innovative blood-based diagnostic tests serve as an ideal diagnostic complement to imaging.
Healthcare providers have long sought additional information to complement current imaging technologies for women who present with abnormal imaging findings; especially for those also confounded by dense breast tissue. In order to be appropriate for use in a clinical setting, this type of blood test needs to be both highly sensitive and specific for breast cancer. A decade’s worth of research and developmental studies were used to aid in the development of a blood test that could be used in conjunction with screening to improve breast cancer detection.
The goal of developing a comprehensive protein signature that analyzes multiple serum protein biomarkers and tumor-associated autoantibodies is to improve the accuracy of breast cancer detection in women with abnormal or unclear findings on imaging. Clinical results show that a blood-based approach can help healthcare providers navigate through the maze of uncertainty in their efforts to accurately detect breast cancer, providing greater confidence and clarity in decision-making. A blood-based approach offers a powerful new approach to breast cancer detection. By identifying biochemical signals of breast cancer, additional pieces of information can be provided to help answer challenging clinical questions and determine the best course of action when next steps are unclear.
For women with abnormal imaging findings, a blood-based approach could effectively rule out invasive breast cancer and ductal carcinoma in situ, irrespective of breast density while also aiding in identification of clinically meaningful lesions. A blood-based approach, based on physiology rather than anatomy also allows for the reduction of false positive and negative results as well as improve the cancer-to-biopsy yield in women with abnormal imaging findings.
Accurate clinical detection of breast cancer depends on the effective use of complementary technologies. If we combine a blood-based approach to the current standard-of-care we can begin to improve breast cancer detection, causing it to be more timely and more accurate.
At Provista Diagnostics, our mission is to develop world-class diagnostic tests for indications in breast and gynecologic cancers. As a leading diagnostics company, our aim is to create, produce and market innovative solutions for unmet clinical needs. Our products and services help to diagnose diseases and inform better clinical decisions, thus enhancing women’s health and quality of life. We do this in a responsible and ethical manner with a commitment to excellence in every aspect of our business.